Biomarkers in Prostate Cancer Treated With Salvage Radical Prostatectomy Following Failure of Focal Ablative Therapies
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostatic Neoplasms
- Sponsor
- Institut Mutualiste Montsouris
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- ability of genomic biomarkers to Measuring tumour aggressiveness
- Last Updated
- 7 years ago
Overview
Brief Summary
The ability of genomic biomarkers to Measuring tumour aggressiveness, and facilitate the selection of therapies in patients who had salvage radical prostatectomy after focal therapy and predict the risk of biochemical recurrence BCR after focal therapy or RP.
Detailed Description
Between 2007 and 2017, 30 patients underwent salvage radical prostatectomy SRP for recurrent localized PCa at our institution (Institute Mutual Montsouris). Primary radiotherapy, brachytherapy and whole-gland treatments were excluded, as to evaluate the true spectrum of morphologic changes caused by the focal emerging ablative modalities. Thirteen SRP after focal ablative therapies FAT (cryotherapy or high intensity focused ultrasound- HIFU or vascular-targeted photodynamic therapy- VTP) were identified from our prospective collected database. Genitourinary pathologists were provided clinical information related to prior therapies and immunohistochemical (IHC) markers were used in the diagnosis of limited primary PC on needle biopsy when necessary. Prostatectomy specimens were processed and the number of tumor foci, size of the dominant focus and pathological stage were recorded. Residual disease was graded according to the Gleason grading system. Treatment-related histologic changes were examined.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Prostate Cancer treated with salvage radical prostatectomy following failure of focal ablative therapies
Exclusion Criteria
- •Primary radiotherapy, brachytherapy and whole-gland treatments
Outcomes
Primary Outcomes
ability of genomic biomarkers to Measuring tumour aggressiveness
Time Frame: molecular analyses
Fragment of Paraffin specimen after RP will be used for the analyses by Biomarkers; MYC, PTEN protein loss, chromosome 8 alterations .